SCIENCE IN THE NEWS DAILY
Promising Alzheimer's Drug Approved for Late-Stage Trials
from USA Today
An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.
Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.
In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.
Read more ...
Connect With Us:
Audio: Using Computing to Advance Toxicology
Chemicals have changed our lives, providing new products and capabilities, but sometimes causing harm to ourselves and the environment... (click the link above to read more).
To view all multimedia content, click "Latest Multimedia."
Receive notification when new content is posted from the entire website, or choose from the customized feeds available.